Cedar Health Research, a Texas-based clinical trial network focused on underserved patients, and Texas Native Health, a Dallas nonprofit serving American Indian and Alaska Native communities, announced on Wednesday that they have opened a new embedded Cedar Health Research site within Texas Native Health.
Established in 2023, the collaborative partnership aims to expand access to clinical research for Native American patients, a population that has historically been underrepresented in clinical trials.
The integrated site allows patients to participate in studies within their trusted care setting, reducing barriers such as travel, limited culturally informed study designs, and longstanding underrepresentation in clinical data.
Initially, the site will support studies addressing conditions disproportionately affecting Native American populations, such as cardiometabolic diseases. Native Americans are 36% more likely than the general US population to have diabetes, and approximately 50% of Native American adults are obese.
Ascletis completes enrolment for US Phase II study of ASC30 in diabetes
Renalytix advances kidneyintelX.Dkd scale-up with laboratory expansion and CE submission
FDA expands approval of Sanofi's Tzield for early-stage type 1 diabetes in young children
EKF Diagnostics acquires Beep Insights technology to expand sports performance offering
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
Lupin's Dapagliflozin Tablets launched in US market
Eli Lilly launches Foundayo weight‑loss pill in the US
Lupin's Dapagliflozin Tablets receive US regulatory approval
Lilly's Foundayo (orforglipron) weight loss pill gains US FDA approval
Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME
AROA Biosurgery completes Symphony trial in patients with diabetic foot ulcers
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA
Kodiak Sciences reports positive Phase 3 results for Zenkuda in diabetic retinopathy